Status:
UNKNOWN
Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China
Lead Sponsor:
Peking University People's Hospital
Conditions:
Giant Cell Tumor of Bone
Eligibility:
All Genders
16-50 years
Brief Summary
This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy.All the patients enrolled will take denosumab according to the protocols....
Detailed Description
This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy. This study only included patients who meet all the following criteria: ...
Eligibility Criteria
Inclusion
- (1) With treatment-naïve sacral GCT firstly treated in our center (for referral patients, only those with definite diagnosis were included); (2)single center lesion (3) Being diagnosed with classic GCTB by puncture pathology prior to treatment (for referral patients, definite diagnosis shall be made by the Pathology Department in our center through pathology consultation on tissue sections); (4) previously denosumab-naïve.
Exclusion
- (1)primary malignant giant cell tumor of bone(2)radiation therapy in history(3)lung metastasis at first diagnosis
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03358212
Start Date
March 1 2018
End Date
June 1 2021
Last Update
November 30 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.